Your browser doesn't support javascript.
loading
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola, Joseph F; Landewé, Robert; McInnes, Iain B; Mease, Philip J; Ritchlin, Christopher T; Tanaka, Yoshiya; Asahina, Akihiko; Behrens, Frank; Gladman, Dafna D; Gossec, Laure; Gottlieb, Alice B; Thaçi, Diamant; Warren, Richard B; Ink, Barbara; Assudani, Deepak; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Coates, Laura C.
Afiliação
  • Merola JF; Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
  • Landewé R; Amsterdam Rheumatology and Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands.
  • McInnes IB; College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Electronic address: iain.mcinnes@glasgow.ac.uk.
  • Mease PJ; Swedish Medical Center and Providence St Joseph Health and University of Washington, Seattle, WA, USA.
  • Ritchlin CT; Department of Medicine, University of Rochester, Rochester, NY, USA.
  • Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
  • Asahina A; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
  • Behrens F; Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Goethe University, Frankfurt am Main, Germany.
  • Gladman DD; Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, ON, Canada.
  • Gossec L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Rheumatology Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
  • Gottlieb AB; Department of Dermatology, The Icahn School of Medicine at Mt Sinai, New York, NY, USA.
  • Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
  • Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, UK.
  • Ink B; UCB Pharma, Slough, UK.
  • Assudani D; UCB Pharma, Slough, UK.
  • Bajracharya R; UCB Pharma, Slough, UK.
  • Shende V; UCB Pharma, Slough, UK.
  • Coarse J; UCB Pharma, Morrisville, NC, USA.
  • Coates LC; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases University of Oxford, Oxford, UK; Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK.
Lancet ; 401(10370): 38-48, 2023 01 07.
Article em En | MEDLINE | ID: mdl-36495881
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Psoriásica / Fator de Necrose Tumoral alfa / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Psoriásica / Fator de Necrose Tumoral alfa / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article